Back to search

Article

Novel Oral-edaravone Attenuates Diastolic Dysfunction of Diabetic Cardiomyopathy via Activating the Nrf2 Signaling Pathway

2021-09-28

Abstract excerpt

<title>Abstract</title> <p>Background Diastolic dysfunction is the most common change of diabetic cardiomyopathy (DCM), but there is no effective clinical treatment at present. Oxidative stress plays a crucial role in the pathophysiological process of diabetic diastolic dysfunction including hypertrophy, apoptosis and fibrosis. The novel Oral-edaravone (OED) alleviates oxidative stress by scavenging free radical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5e118d70-9e89-5306-b3ec-b8ac9301e199
DOI
10.21203/rs.3.rs-936670/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel Oral-edaravone Attenuates Diastolic Dysfunction of Diabetic Cardiomyopathy via Activating the Nrf2 Signaling PathwayDOI 10.21203/rs.3.rs-936670/v1
Select a neighboring publication to make it the new centre.